BCL2L1 and melanoma: As previous studies reported that the Bax/Bcl-xL ratio is a valid indicator of melanoma cell sensitivity to therapy by apoptosis induction (Raisova et al., 2001; Kale et al., 2018), we determined this ratio in each experimental condition based on the WB protein expression levels of the two proteins.